Cargando…

Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression

Antidepressants are among the most widely prescribed medications, yet only 35–45% of patients achieve remission following an initial antidepressant trial. The financial burden of treatment failures in direct treatment costs, disability claims, decreased productivity, and missed work may, in part, de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winner, J, Allen, J D, Anthony Altar, C, Spahic-Mihajlovic, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625917/ https://www.ncbi.nlm.nih.gov/pubmed/23511609 http://dx.doi.org/10.1038/tp.2013.2

Ejemplares similares

The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes
por: Benitez, Joachim, et al.
Publicado: (2015)

Pharmacogenomic testing and outcome among depressed patients in a tertiary care outpatient psychiatric consultation practice
por: Rundell, J R, et al.
Publicado: (2011)

Utilizing a medical questionnaire to predict anxiety and depression in outpatients
por: Kajiwara, Hideki, et al.
Publicado: (2016)

Using a pharmacogenomic algorithm to guide the treatment of depression
por: Hall-Flavin, D K, et al.
Publicado: (2012)

Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical Utility
por: Winner, Joel G., et al.
Publicado: (2015)

Web Resources for Pharmacogenomics
por: Zhang, Guoqing, et al.
Publicado: (2015)

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial
por: Tiwari, Arun K., et al.
Publicado: (2022)

Factor structure of the Hospital Anxiety and Depression Scale in Japanese psychiatric outpatient and student populations
por: Matsudaira, Tomomi, et al.
Publicado: (2009)

Psychiatric pharmacogenomic testing in clinical practice
por: Mrazek, David A.
Publicado: (2010)

Correction: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial
por: Tiwari, Arun K., et al.
Publicado: (2022)

Application of pharmacogenomics in psychiatric practice: The road ahead
por: Mohan, Prafull, et al.
Publicado: (2021)

Pharmacogenomics in depression and antidepressants
por: Bondy, Brigitta
Publicado: (2005)

The use of CAM providers and psychiatric outpatient services in people with anxiety/depression: a cross-sectional survey
por: Hansen, Anne Helen, et al.
Publicado: (2016)

Reliability and Validity of the Korean Version of the Lifetime Stressor Checklist-Revised in Psychiatric Outpatients with Anxiety or Depressive Disorders
por: Choi, Kang Rok, et al.
Publicado: (2017)

Metabolic syndrome among psychiatric outpatients with mood and anxiety disorders
por: Hung, Ching-I, et al.
Publicado: (2014)

Predictive factors for medical resource utilization among Taiwan’s psychiatric inpatients
por: Lin, Chin-Ming, et al.
Publicado: (2014)

Use of combinatorial pharmacogenomic testing in two cases from community psychiatry
por: Fields, Eve S, et al.
Publicado: (2016)

Utilizing yeast chemogenomic profiles for the prediction of pharmacogenomic associations in humans
por: Silberberg, Yael, et al.
Publicado: (2016)

Exploratory Factor Analysis of the Beck Anxiety Inventory and the Beck Depression Inventory-II in a Psychiatric Outpatient Population
por: Lee, Kounseok, et al.
Publicado: (2018)

Systematic review of economic evaluation studies in psychiatric pharmacogenomics
por: Mitropoulou, C., et al.
Publicado: (2021)

Outpatient psychiatric service utilization during the Covid-19 pandemic
por: Shirzad, Fateme, et al.
Publicado: (2022)

Anxiety disorders: Psychiatric comorbidities and psychosocial stressors among adult outpatients
por: Nel, Carla, et al.
Publicado: (2018)

A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam
por: Campbell, Ciarán, et al.
Publicado: (2022)

Dataset of the first report of pharmacogenomics profiling in an outpatient spine setting
por: Cottrill, Ethan, et al.
Publicado: (2021)

Depression and anxiety disorders among gastroenterologic outpatients
por: Tasci, Ilker, et al.
Publicado: (2014)

Prevalence and severity of Anxiety and Depression among Primary caregivers with correlation to their Psychiatric outpatients diagnostic entity according to ICD-10
por: Afridi, I.
Publicado: (2022)

Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients
por: Dunlop, Boadie W.
Publicado: (2020)

Unintentional Injuries among Psychiatric Outpatients with Major Depressive Disorder
por: Hung, Ching-I, et al.
Publicado: (2016)

The North Italian innovative project for common psychiatric disorders: Evaluating the output of a treatment model of an outpatient clinic for anxiety and depression
por: Caselli, Ivano, et al.
Publicado: (2023)

Clinical utility of pharmacogenomics in the management of hepatitis C
por: Trinks, Julieta, et al.
Publicado: (2014)

Editorial: The utilization of bench-to-bedside approaches in pharmacogenomics
por: Rytkin, Eric, et al.
Publicado: (2023)

PharmGKB: A worldwide resource for pharmacogenomic information
por: Barbarino, Julia M., et al.
Publicado: (2018)

Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(®)) to Guide Treatment of Patients with Depression and/or Anxiety
por: Najafzadeh, Mehdi, et al.
Publicado: (2017)

Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
por: Roseberry, K., et al.
Publicado: (2023)

DEPRESSIVE DISORDERS IN PSYCHIATRIC OUTPATIENT CLINIC ATTENDEES IN EASTERN SAUDI ARABIA
por: Abumadini, Mahdi S.
Publicado: (2003)

Real-World Functioning in Psychiatric Outpatients: Predictive Factors
por: Bozzatello, Paola, et al.
Publicado: (2022)

The relationship of psychological reactance, health locus of control and sense of self-efficacy with adherence to treatment in psychiatric outpatients with depression
por: De las Cuevas, Carlos, et al.
Publicado: (2014)

Prevalence of Depression and Anxiety in Outpatients with Chronic Airway Lung Disease
por: Ryu, Yon Ju, et al.
Publicado: (2010)

Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders
por: Chang, Florence CF, et al.
Publicado: (2014)

Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications
por: Tanner, Julie-Anne, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a064kb04evhsm404v8066ljuih